FDAnews
www.fdanews.com/articles/199058-valneva-dynavax-inks-15-billion-covid-19-vaccine-supply-deal-with-uk

Valneva, Dynavax Inks $1.5 Billion COVID-19 Vaccine Supply Deal With UK

September 15, 2020

The UK government has signed a $1.5 billion agreement with Valneva to supply up to 190 million doses of the French company’s COVID-19 vaccine — enough to provide multiple doses to the UK’s population of almost 68 million.

Under the agreement, the UK will pay $558 million for 60 million doses of VLA2001, which will be supplied in the second half of 2021. The deal includes an option to purchase 40 million more doses in 2022 and an additional 30 million to 90 million doses between 2023-2025.

Berkeley, Calif.-based Dynavax, which is a party to the agreement, will supply up to 190 million doses of its CpG1018 adjuvant for the vaccine.

Valneva said it expects to begin clinical testing of VLA2001 at the end of the year and anticipates regulatory approval in the second half of 2021 if the results are favorable.

The UK has already secured vaccine supply deals with multiple vaccine developers, including AstraZeneca, Johnson & Johnson, Novavax, Sanofi/GlaxoSmithKline and Pfizer/BioNTech. — Jordan Williams